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OBJECTIVES: Clinical trials of oncology products often allow crossover of control
patients to the treatment arm following disease progression. This can underesti-
mate a product’s overall survival (OS) and raises challenges for cost-effectiveness
analyses compared.METHODS: A lifetime model compared the cost-effectiveness
of a hypothetical pancreatic cancer therapy (CRG001) to gemcitabine. Gemcitabine
survival data were derived from published studies. A hazard ratio of 0.55 was
assumed for CRG001. CRG001 cost $2500 every 2 weeks for a maximum of 12 cycles
and gemcitabine cost $200 every 1week for amaximumof 24 cycles. Analyseswere
conducted: 1) 0%; 2) 50%; and 3) 85% crossover of gemcitabine patients to CRG001.
Patient crossover occurred at the time of disease progression. Crossover patients
received the CRG001 hazard ratio. Patients progressing in CRG001were assumed to
receive palliative care. A secondary analysis allowed 50% crossover but excluded
second-line costs of CRG001. Costs and outcomeswere discounted at 5%. RESULTS:
The cost per QALY gained for CRG001 comparedwith current carewas $81,352with
no cross-over, $69,292 with 50% crossover and 40,992 with 85% crossover. In the
analysiswhere the cost of CRG001was excluded in crossover patients, the ratiowas
$140,118. CONCLUSIONS: The first three analyses illustrate that CRG001 cost-ef-
fectiveness decreases with increasing cross-over of gemcitabine patients, if the
costs of CRG001 for crossover patients are included. In our experience, however,
reimbursement agencies often require a primary analysis that excludes second-
line costs of the study drug for patients that cross-over. This analysis yields a high
ratio that could lead to a negative reimbursement decision. In this case, where
second-line CRG001 costs are excluded, adjustment of OS for crossover of gemcit-
abine patients is required. Overall, consideration must be given to the extent and
potential impact of crossover when conducting cost-effectiveness analysis of new
oncology products.
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OBJECTIVES: To quantify patients’ benefit-risk preferences for benefits, toxicities,
and serious adverse events of advanced RCC treatments. METHODS: Adult resi-
dents in the United States, with a self-reported diagnosis of RCC completed a
web-enabled choice-format conjoint survey consisting of a series of 10 treatment-
choice questions, and a pair of hypothetical RCC medication profiles. Each profile
had different attributes, i.e., efficacy [PFS], tolerability [fatigue, stomach problems,
mouth sores, hand-foot syndrome (HFS)], serious adverse events (lung damage and
liver failure), andmode of administration. Treatment-choice questions were based
on a predetermined experimental design with known statistical properties. Ran-
dom-parameters logit was used to estimate relative preference weights for each
attribute level, mean relative importance weights; and calculate risk tolerance for
each adverse event for different improvements in PFS. RESULTS: A total of 272
respondents completed the survey. A 7-month improvement in PFS was the most
important attribute. Remaining attributes were ranked in decreasing order of im-
portance: eliminating severe fatigue (7.0; 95% CI: 4.6-9.4), eliminating severe stom-
ach problems (7.0; 95% CI: 4.7-9.3), eliminating a 2% liver-failure risk (6.1; 95% CI:
4.0-8.2), eliminating severe mouth sores (5.7; 95% CI: 3.7-7.7), eliminating severe
HFS (4.5; 95% CI: 2.7-6.4), eliminating a 2% lung-damage risk (4.1; 95% CI: 2.5-5.8),
and switching from infusion once aweek to 1 pill once a day (2.5; 95%CI: 1.4-3.6). To
increase PFS by 1 month (baseline: 3 - 4 months), patients accepted a maximum
level of lung damage risk of 1.0% (95% CI: 0.8% - 1.4%) and liver failure risk of 0.7%
(95% CI: 0.4% - 1.0%). A 7-month improvement in PFS was 2 times as important as
eliminating severe HFS and a 2.0% risk of lung damage (P  0.05). CONCLUSIONS:
PFS was the most important outcome for RCC patients while severe fatigue and
severe stomach problems were rated as the most troublesome toxicities.
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DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED QUESTIONNAIRE
TO ASSESS THE QUALITY OF LIFE OUTCOMES OF INDIAN BREAST CANCER
PATIENTS
Deshpande P, Chittkathopottamal AN, Bommareddy LS, Mallasamy S
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OBJECTIVES: To develop and validate a patient-reported questionnaire to assess
the quality of life (QOL) outcomes of Indian breast cancer (BC) patients.METHODS:
A 27-item questionnaire was developed by literature review, patient interviews
(n6) and expert opinions (n15). The 24-item questionnaire was finalized. Total
11 domains were considered. The questionnaire was translated to local languages
and then it was administered to BC patients (n30) irrespective staging of cancer
and type of therapy. The patients were interviewed and the responses were ob-
tained. Internal consistency, acceptability, content validity, test-retest reliability of
the questionnaire was determined and assessment the scores was performed
statistically. RESULTS: A 24-item questionnaire was developed as per literature
review, patient interviews and expert opinions. Cronbach’s alpha value for the
questionnaire was 0.93. Patients understood the questionnaire and found the
items to be relevant indicating content validity. The statistical assessment of the
scores was not showing the association between scores with age or stage of BC as
sample size was less. CONCLUSIONS: The questionnaire shows good internal con-
sistency, acceptability, content validity and test-retest reliability. It can be used to
determine the QOL of BC patients. To our knowledge there is no other question-
naire to determine the QOL outcomes of Indian BC patients. For better results the
instrument is needed to be used in larger population.
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TRANSLATION AND LINGUISTIC VALIDATION OF THE FACT-TH18 FOR USE
WITH CANCER PATIENTS WITH THROMBOCYTOPENIA WORLDWIDE
Arnold B, Dhar J, Parks-Vernizzi E, Debb S
FACITtrans, Elmhurst, IL, USA
OBJECTIVES: Translation of patient reported outcomes (PRO) measures is an es-
sential component of the researchmethodology required when preparing for mul-
tinational clinical trials. One suchmeasure is the Functional Assessment of Cancer
Therapy-Thrombocytopenia 18 questionnaire (FACT-Th18), which evaluates the
quality of life (QOL) of cancer patients with thrombocytopenia. METHODS: This
study set out to linguistically validate the FACT-Th18 scale for use in China, Greece,
HongKong, Japan, India, Israel, Korea, Taiwan andThailand. The combined sample
consisted of 160 patients (81males/79 females) diagnosed with thrombocytopenia.
Patientmean agewas 46 years, and at the time of administration, 146 patientswere
receiving treatment. The sample consisted of patients who speak Arabic, Chinese-
Traditional, Chinese-Simplified, Greek, Gujarati, Hebrew, Hindi, Japanese, Kan-
nada, Korean, Malayalam, Marathi, Punjabi, Tamil, Telugu and Thai. The FACT-
Th18 was translated based on the established FACIT methodology. Patients
completed the respective translated questionnaire corresponding to their primary
language and then participated in a cognitive interview to determine if there were
any problems with the translations or item content. Quantitative analyses were
performed on the combined sample and participant comments were analyzed
qualitatively in order to confirm the validity of the translations. RESULTS: During
the translation process terms such as “petechiae”, “pinpoint bruising” and “platelet
transfusions” proved difficult to translate. The FACT-Th18 translations proved rel-
evant to patients from a wide range of countries and were well understood. Very
few items required adjustment to translations as a result of pilot-testing.
CONCLUSIONS: The FACT-Th18 demonstrated linguistic validity across all 16 lan-
guages. The translations are considered acceptable for PRO assessment in interna-
tional research and clinical trials.
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OBJECTIVES: Estimating prevalence rates for raremedical conditions such as renal
cell carcinoma (RCC) at state level by age and sex is difficult due to the paucity of
available data resources. Available information may be fragmented because of a
lack of national level surveillance. The use of commercialmedical claim data alone
is insufficient for estimation because the use of these data tends to result in biased
estimates due to business practices of managed care organization. METHODS:
Invision Data Mart and the US census data were used to address this problem. The
study inclusion criteria for defining RCC patients was age of 18 years or older
without prior history of HIV/AIDS, HVB, or HVC diagnoses and had at least 2 out-
patient medical claim with an associated ICD9 code of 189.0. First, we estimated
prevalence rates for themedical conditions by state, age, and sex using ICD9 codes
from the commercial data (2002-2010). Then, reanalyzed using post-stratification
weights derived from the 2010 Census data to reflect the state, age, and sex distri-
bution of the US population. RESULTS: The sum of the adjusted state population
weights yielded a total that was similar to the 2010 US census data, and adjusted
values suggest that the overall 2010 US RCC prevalence is approximately 85k. Since
there is no state level prevalence information for RCC by age and sex available, an
indirect comparison was made by comparing the overall prevalence from Kantar
Health (CancerMpact®). The overall prevalence estimates were similar; Kantar
Health: 86,853 versus Study Estimate: 84,712. CONCLUSIONS: This method pro-
duced prevalence rates that take important health care related factors into account
in the estimation process. We recommend the use of this combined approach for
the estimation of prevalence rates of rare disease conditions and procedures.
INFECTION – Clinical Outcomes Studies
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OUTCOMES ASSOCIATED WITH SEVERE COMORBIDITIES IN HOSPITALIZED
CASES OF HIV/AIDS
Villa L1, Skrepnek G2
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OBJECTIVES: To assess economic and clinical characteristics of severe comorbidi-
ties during inpatient hospitalizations in persons with HIV/AIDS. METHODS: The
Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utiliza-
tion Project (H-CUP) Nationwide Inpatient Sample (NIS) was used in this retrospec-
tive database study spanning 2005-2009. Inpatient cases of HIV/AIDS among per-
sons 18 years of age or older were used as inclusion criteria. Key clinical
comorbidities analyzed included organ insufficiency/failure, cancers, heart failure,
pulmonary circulation disorders, coagulopathies, fluid/electrolyte disorders, and
wasting syndromes/weight loss. Outcomes of inpatient mortality and hospital
charges were assessed via multivariate logistic and gamma regression, respec-
tively, after controlling for comorbidities, patient demographics, hospital charac-
teristics, payer, and lengths of stay. RESULTS: There were 1,227,718 overall inpa-
tient cases of HIV/AIDS from 2005-2009 in the United States, averaging 44.8 (10.7)
years of age, 6.7 (9.0) days for length of stay, and inpatient charges of $36,004
(59,303). Mortality occurred in 41,609 cases, constituting 3.4% of all HIV/AIDS
hospitalizations and averaging 47.0 (11.1) years of age, 13.4 (17.4) days for length
of stay, and inpatient charges of $104,558 (136,254). Fluid/electrolyte disorders
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occurred in 57.1% of mortality cases, followed by sepsis/septicemia (39.3%), coagu-
lopathies (23.8%), renal failure (19.4%) wasting syndrome/weight loss (18.4%), liver
disease (16.2%) heart failure (9.7%), lymphoma (6.6%), metastatic cancer (3.3%),
pulmonary circulation disorders (2.9%), and solid tumors (2.8%). Regression analy-
ses found that increased mortality and charges were associated with each afore-
mentioned comorbidity except wasting syndromes/weight loss. Significant
(p0.05) odds ratios were observed for inpatient mortality ranging from 1.17 (renal
failure) to 8.06 (sepsis/septicemia) and exponentiated beta-coefficients for charges
ranging from 1.03 (liver disease) to 1.33 (sepsis/septicemia). Various cancers were
associated with substantially worse outcomes. CONCLUSIONS: An increased un-
derstanding of severe comorbidities inHIV/AIDS is of continued importancewithin
hospital settings. Sepsis/septicemia and cancer is particularly associated with in-
creased inpatient mortality and charges.
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OBJECTIVES: Systematically review all randomized trials evaluating licensed rota-
virus vaccines for efficacy and safety on diarrhoea, hospital admission, death and
serious adverse events.METHODS: Electronic searches strategies were performed
until October 2011. Trial eligibility, data extraction and quality assessment were
performed independently by two reviewers. Dichotomous data were pooled using
the risk ratio (RR) and 95% CI. GRADE was used to evaluate evidence quality.
RESULTS: Forty-three RCTs including 190,551 participants were identified; 31 trials
assessed RV1, and 12 RV5. In children  1 year, RV1 (RR0.20, 95%CI0.11 to 0.35; 7
trials, 35,004 participants) and RV5 (RR0.23, 95%CI 0.08 to 0.71; 3 trials, 6953 par-
ticipants) are highly efficacious against severe rotavirus diarrhoea cases and/or
rotavirus diarrhea requiring hospitalization. For all-cause diarrhea, RV1 reduces
severe cases by 42% (RR0.58, 95% CI 0.40 - 0.84; 8291 participants), and RV5 by 72%
(RR0.28, 95%CI 0.16 - 0.48). Both vaccines were also efficacious during the second
year of life (RV1: RR0.16, 95%CI 0.12 - 0.21; 8 trials, 32,854 participants; RV5:
RR0.44, 95%CI 0.22 - 0.88; 4 trials, 9783 participants). For all-cause diarrhoea, RV1
reduces severe cases by 51% (RR0.49, 95%CI 0.40 - 0.60; 2 trials, 6269 participants).
Both vaccines had no impact on mortality, but serious adverse events following
vaccination, including intussusception, were not more common than following
placebo. CONCLUSIONS: RV1 and RV5 vaccines are efficacious and relatively safe.
These data support the WHO’s global vaccine recommendation. Potential reduced
vaccine efficacy in low income countries needs to be addressed. Ongoing safety
monitoring should be continued in countries that have introduced rotavirus vac-
cination.
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HEALTH OUTCOMES WITH DAPTOMYCIN (DAP) IN THE TREATMENT OF
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS BACTEREMIA (MRSA-B)
WITH VANCOMYCIN (VAN) MINIMUM INHIBITORY CONCENTRATION (MIC)  2
G/Ml
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OBJECTIVES: MRSA-B is associated with high morbidity and cost. Guidelines rec-
ommend alternative treatment when VAN MICs are 2. DAP effectiveness in
MRSA-B patients (pts)with elevatedVANMICs is an important real-world question.
This analysis evaluates outcomes relevant to pts and institutions including clinical
success, DAP-related length of stay (LOS), and infection-related readmission.
METHODS: All pts with MRSA-B were identified in CORE 2010, a retrospective,
multicenter, observational registry of staphylococcal bacteremia pts with VAN
MIC2 mg/L per local lab. Investigators assessed pt outcome (cured, improved,
failed, nonevaluable) at the end or at last contact of DAP therapy. Pt characteristics
and outcomes are based on the efficacy population. All pts were included in the
safety analysis. RESULTS: A total of 158 pts with MRSA-B were identified; 142 had
initial VANMIC2 and were evaluable for outcome: 47%male, 40%65 years, 27%
CrCl 30mL/min, 21% on dialysis, 22% treated in the ICU. Frequent concurrent
infections included skin and skin structure (12%), endocarditis (9%), bone/joint
(8%). Median (min,max) DAP dose and duration were 6 mg/kg (4,11) and 13.5 days
(2,62), respectively. 80% (114/142) received prior antibiotics; (88% of which was
VAN). Success occurred in 89% overall, with no difference between first (89% [25/
28]) and second-line (89% [101/114]) DAP treatment. Time to clinical response
ranged from 1-27 days (median2). Median (min,max) DAP-related LOS was 9 days
(2,44). 21 pts (15%) were evaluated in the ER within 60 days of completing DAP
therapy. Infection-related readmission occurred in 10 pts (7%). 7 pts experienced 9
AEs possibly related to DAP; 5 pts discontinued DAP due to AE. Overall mortality
rate was 12%; 4 pts died within 7 days. CONCLUSIONS: This evaluation of real-
world effectiveness demonstrates that DAP may be a useful agent for MRSA-B
isolates with a VAN MIC2. Additional comparative effectiveness and resource
utilization studies are warranted.
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EFFICACY AND SAFETY OF THE COMBINATION TENOFOVIR (TDF)/
EMTRICITABINA (FTC)  EFAVIRENZ (EFV) IN TREATMENT OF NAIVE ADULT
PATIENTS WITH HIV-1 INFECTION: A SYSTEMATIC REVIEW
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OBJECTIVES: The objective was to evaluate the efficacy and safety of the combina-
tion TDF/FTCEFV compared to the available treatment combinations in Mexico.
METHODS: We conducted a systematic review using the Cochrane guidelines of
randomized clinical trials in PUBMED,EMBASE, LILACS ANDARTEMISA to compare
TDF/FTCEFV, ABC/3TCEFV, ZDV/3TCEFV, LPV/rTDF/FTC and LPV/rABC/
3TC in naïve adult patients with HIV-1 infection. Themain outcome variables were
RNA HIV-1 copies less than 50/mm3 at 48 and 96 weeks, and grade 2-4 adverse
effects at 48 effects. We used a random model effects for the pooled analysis.
RESULTS:We included 6 articles, 4 at 48 weeks and 2 at 96 weeks. The arms were
grouped by the tree elements of HAART. The combination TDF/FTCEFV was the
most frequently used (3 studies). At 48 and 96 weeks the pooled probabilities to
have 50 RNA copies/ml for TDF/FTCEFVwere 0.771 (CI95% 0.711 – 0.821; n681)
and 0.670 (CI95% 0.607 – 0.727; n232); ZDV/3TCEFV 0.704 (CI95% 0.643 – 0.758;
n243) and 0.610(CI95% 0.546 – 0.671; n231); LPV/rABC/3TC 0.680 (CI95% 0.629 –
0.727; n343) and 0.600(CI95% 0.527 – 0.631; n343); ABC/3TCEFV 0.677 (CI95%
0.509 – 0.809; n437); and LPV/rTDF/FTC 0.670 (CI95% 0.619 – 0.718; n345) and
0.580(CI95% 0.527 – 0.631; n345) respectively. The adverse events rates (hypersen-
sitivity and diarrhea) at 48 weeks were for TDF/FTCEFV 0.005 (CI95% 0.001 – 0.036)
and 0.050 (CI 95% 0.017-0.136) respectively, TDF/FTCEFV show fewer adverse
events than compared to the other treatment regimens (LPV/rTDF/FTC, ABC/
3TCEFV and LPV/rABC/3TC ). At 48 weeks the discontinuation rate for EFV 
ZDV/3TCwas 0.91,( n254) and for LPV/r TDF/FTC 0.041 (n170). CONCLUSIONS:
The combination TDF/FTCEFV is themost studied combination and it is clinically
effective at 48 and 96 weeks, with good safety profile.
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SYSTEMATIC REVIEW OF INTERFERON FREE BASED REGIMENS FOR CHRONIC
HEPATITIS C TREATMENT
Aggarwal S
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OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global
epidemics with significant unmet need and disease burden. One of the major lim-
itations of current treatments is the need for 12 or 6 months of Interferon based
therapy, which has tolerability and toxicity issues for many patients. During last
2-3 years several new agents have been tested in clinic, which have shown prom-
ising results as non-interferon based therapy. Goal of this study was to review the
clinical efficacy and safety profile of non-interferon based therapies for HCV
treatment.METHODS:We searched the MEDLINE, and abstracts from AASLD and
EASL until May 2011. Studies were selected for clinical trials on direct acting agents
for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxic-
itywas evaluated as secondary endpoint. Aggregated datawere further analyzed to
understand comparative safety and efficacy. RESULTS: Until May 2011, results of
five eligible HCV clinical trials for interferon free regimens were available. Overall,
treatment with combination of protease and polymerase inhibitor showed dra-
matic viral load reduction after 2 weeks of treatment. The combination of PSI-7977
and PSI-938 showed 93% viral clearance after 14 days (n16). The combination of
RG7227 andRG7128 demonstrated 5.1 log reduction in viral load in treatment naive,
and 4.9 log reduction in null responder patients after 14 days of treatment. The
combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null
responder patients. One study evaluating VX-222 and Telaprevir combination was
discontinued due to viral breakthrough. Several studies are currently on-going
whose data would be available in 2011-2012. CONCLUSIONS:Non-interferon based
therapies have shown impressive viral load reduction in short term studies. How-
ever, more data for SVR, viral breakthrough and resistance is needed to confirm
their safe use in HCV infected population.
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IMMUNODEFICIENCY VIRUS IN VETERAN PATIENTS IN THE UNITED STATES
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OBJECTIVES: To assess the clinical and economic burden of the human immuno-
deficiency virus (HIV) in the US veteran population. METHODS: A retrospective
study including patients diagnosed with HIV between October 1, 2005 and Septem-
ber 30, 2010 was conducted using the Veterans Health Affairs Medical SAS Data-
sets. Health care resource utilization and costs were assessed in the 12-month
follow-up period. Patients’ demographic, clinical and discharge statuseswere com-
pared using Chi-square testing and standardized differences. Student t-tests were
used for the means of continuous variables. Mortality and survival rates were
calculated using the Kaplan and Meier method and the PROC LIFETEST procedure.
RESULTS:Among all study patients diagnosedwith HIV (n29,388), mortality rates
in the 12-month follow-up period were 15.79% (n4,635), and 5.15% for patients
under age 40, 16.25% for patients age 40 to 65, and 30.01% for patients age 65 and
over. The most commonly prescribed medications were emtricitabine/tenofovir
(2.39%), efavirenz (2.34%), sulfamethoxazole/trimethopri (1.88%), lamivudine/zid-
ovudine (1.81%), lopinavir/ritonavir (1.76%), and atazanavir (1.68%). Themost com-
monly performed laboratory tests were for sodium (3.38%), potassium (3.27%), cre-
atinine (3.25%), chloride (3.25%), glucose quant (3.18%), and carbon dioxide content
(2.94%). For patients with HIV, the average numbers of inpatient (0.48), emergency
room (ER) (0.82), physician office (35.31) and outpatient visits (35.56) were calcu-
lated per patient, separately. The percentages of inpatient (24.62%), ER (35.01%),
physician office (99.90%) and outpatient visits (99.93%) were also computed, which
led to the following costs for inpatient ($7,828), ER ($329), physician office ($14,080)
and outpatient visits ($14,450). CONCLUSIONS: This study found that emtricit-
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